Shield Therapeutics PLC PDMR Acquisition of Shares (5457W)

TIDMSTX

RNS Number : 5457W

Shield Therapeutics PLC

17 April 2019

Shield Therapeutics plc

("Shield" or the "Company")

PDMR Acquisition of Shares

London, UK, 17 April 2019, Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru(R), announces that James Karis, Chairman of the Company, has acquired 46,000 Ordinary Shares in the Company on 15 April 2019 for consideration of GBP0.815 per Ordinary Share and 4,000 Ordinary Shares in the Company on 16 April 2019 for consideration of GBP0.81 per Ordinary Share. Following the transaction, Mr Karis holds 86,667 shares, representing 0.001% of the Company's issued share capital.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                       James Karis 
     -------------------------  ---------------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------------- 
 a)   Position/status            Chairman 
     -------------------------  ---------------------------------------------- 
 b)   Initial                    Initial Notification 
       notification/ 
       Amendment 
     -------------------------  ---------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------------- 
 a)   Name                       Shield Therapeutics plc 
     -------------------------  ---------------------------------------------- 
 b)   LEI                        213800G74QWY15FC3W71 
     -------------------------  ---------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     ------------------------------------------------------------------------- 
 a)   Description                Ordinary shares of 1.5p each in the capital 
       of the                     of the Company 
       financial                  ISIN of Ordinary Shares: GB00BYV81293 
       instrument, 
       type 
       of instrument 
       Identification 
       code 
     -------------------------  ---------------------------------------------- 
 b)   Nature                     Acquisition of Ordinary Shares 
       of the 
       transaction 
     -------------------------  ---------------------------------------------- 
 c)   Price(s)                   GBP0.815 ($1.0705) per Ordinary Share 
       and                        Volumes: 46,000 
       volume(s)                  GBP0.81 ($1.0602) per Ordinary Share 
                                  Volumes: 4,000 
                                  The trades were settled in US dollars at the 
                                  above amounts 
     -------------------------  ---------------------------------------------- 
 d)   Aggregated 
       information                 50,000 
                                   GBP40,730 
        *    Aggregated volume 
 
 
 
        *    Price 
     -------------------------  ---------------------------------------------- 
 e)   Date                       46,000 Ordinary Shares - 15 April 2019 
       of the                     4,000 Ordinary Shares - 16 April 2019 
       transaction 
     -------------------------  ---------------------------------------------- 
 f)   Place                      London Stock Exchange, AIM Market 
       of the 
       transaction 
     -------------------------  ----------------------------------------------

For further information please contact:

 
 Shield Therapeutics plc                                 www.shieldtherapeutics.com 
 Carl Sterritt, Chief Executive 
  Officer                                                       +44 (0)20 7186 8500 
 Tim Watts, Chief Financial Officer 
 
 Nominated Advisor and Broker 
 Peel Hunt LLP 
 James Steel/Dr Christopher Golden                              +44 (0)20 7418 8900 
 
 Financial PR & IR Advisor 
 Walbrook PR                           +44 (0)20 7933 8780 or shield@walbrookpr.com 
                                              +44 (0)7980 541 893 / +44 (0)7841 917 
 Paul McManus / Helen Cresswell                                                 679

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru(R), for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru(R) is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27(th) July 2019. For more information please visit www.shieldtherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations and include statements related to the timing of future results of Feraccru trials and the timing and success of the Group's regulatory plans and commercial strategy for Feraccru. These statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties, many of which are beyond our control, that may cause actual results, performance or achievements to be materially different from management's expectations expressed or implied by the forward-looking statements, including, but not limited to, risks associated with the regulatory approval process, the Group's business and results of operations, competition and other market factors. The forward-looking statements made in this press release represent management's expectations as of the date of this press release, and except as required by law, the Group disclaims any obligation to update any forward-looking statements contained in this release, even if subsequent events cause our views to change.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHBUGDSXUBBGCR

(END) Dow Jones Newswires

April 17, 2019 11:56 ET (15:56 GMT)

Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jun 2024 to Jul 2024